AG真人官方

Ascendis Pharma A/S (ASND) filing a Form 144 notifies the market of a proposed sale of 3,000 American Depositary Shares with an aggregate market value of $578,385. The shares represent part of 55,635,376 shares outstanding and are scheduled for sale on 08/20/2025 through Goldman Sachs & Co. LLC. The filer reports acquisition of the 3,000 ADS on 08/20/2025 via warrant exercise and payment in cash. The filing states there were no sales by the filer in the prior three months and includes the standard Rule 144 representation about no undisclosed material adverse information.

Ascendis Pharma A/S (ASND) filed a Form 144 notifying the proposed sale of 9,375 American Depositary Shares on 08/15/2025 through Merrill Lynch on NASDAQ. The filing reports an aggregate market value of $1,826,403.05 and total shares outstanding of 60,454,589. The shares were acquired the same day by warrant exercise from Ascendis Pharma A/S, with cash payment. The filer reports no securities sold in the past three months. The notice includes the standard signature representation that the seller is not aware of any undisclosed material adverse information.

Form 144 notice for Ascendis Pharma A/S (ASND): The filer proposes to sell 25,000 American Depositary Shares on 08/14/2025 through Merrill Lynch on NASDAQ. The aggregate market value of the proposed sale is $4,789,998.27. The shares were acquired the same day on 08/14/2025 by warrant exercise from Ascendis Pharma A/S and paid in cash. The filing reports 60,454,589 shares outstanding and indicates no securities sold in the past three months by the account. The notice includes the seller's certification that no undisclosed material adverse information is known.

Janus Henderson Group plc reported a significant minority holding in Ascendis Pharma A/S American Depositary Shares. The filing shows an aggregate holding of 4,427,792 ADSs, representing 8.0% of the class, with shared voting and shared dispositive power over those shares. The filer is organized in Jersey and lists a UK principal office; the issuer is headquartered in Hellerup, Denmark.

One Janus Henderson subsidiary, JHIUS, may be deemed the beneficial owner of 4,328,772 ADSs (7.8%) with corresponding shared voting and dispositive power. The filing includes a certification that the securities were acquired in the ordinary course of business and not to change or influence control, and attaches a power of attorney authorizing named officers to file required reports.

Ascendis Pharma A/S submitted a Form 144 reporting a proposed sale of 10,000 American Depositary Shares through Merrill Lynch on NASDAQ with an aggregate market value of $1,913,224.99 and an approximate sale date of 08/13/2025.

The filing states the shares were acquired on 08/13/2025 by warrant exercise from Ascendis Pharma A/S, with cash payment. Total shares outstanding are listed as 60,454,589. The filer reports no securities sold in the past three months and attests they do not know of any undisclosed material adverse information regarding the issuer.

Ascendis Pharma A/S (ASND) filed a Form 144 reporting a proposed sale of 2,158 ordinary shares. The filing lists an aggregate market value of 412,319.34 and 60,454,589 shares outstanding. The shares are to be sold on NASDAQ with an approximate sale date of 08/13/2025.

The securities were acquired on 08/13/2025 through Restricted Stock Vesting from Ascendis Pharma A/S and the payment nature is listed as Compensation. The filing indicates no securities sold during the past three months and includes the standard signature representation that the seller does not possess undisclosed material adverse information. The form does not name the person for whose account the securities are to be sold.

Ascendis Pharma A/S reported that its board granted an aggregate of 28,480 warrants to certain employees. Each warrant permits subscription for one ordinary share with an exercise price of $195.98, set equal to the closing price of the company鈥檚 American Depositary Shares on the grant date. The company amended its Articles of Association to authorize the grant and included those Articles as an exhibit.

The warrants vest subject to continued service: 25% vest after one year and the remaining 75% vest monthly at 1/36th starting one year after grant, with earlier vesting possible on certain exit events. After this grant, 1,859,873 warrants remain available for future awards. The report is incorporated by reference into the company鈥檚 S-8 and F-3 registration statement coverage.

Capital International Investors reported beneficial ownership of 3,109,225 shares of Ascendis Pharma A/S common stock, representing 5.6% of the 55,754,437 shares believed outstanding. The filing shows sole voting power for 3,099,512 shares and sole dispositive power for 3,109,225 shares. The shares reported are Depository Receipts that represent common stock. The filing classifies the filer as an investment adviser (IA) and includes a certification that the position is held in the ordinary course of business and not for the purpose of changing or influencing control.

Form 144 reports a proposed sale of 10,000 American Depositary Shares (ADS) of Ascendis Pharma (ASND) with an aggregate market value of $1,925,734.17. The sale is to be handled through Merrill Lynch on NASDAQ and is scheduled for 08/12/2025. Based on the figures provided, the implied price per ADS is approximately $192.57.

The shares were acquired the same day by warrant exercise from Ascendis Pharma A/S and paid for in cash. The 10,000 ADS represent about 0.0165% of the 60,454,589 ADS outstanding reported in the filing. The filer notes no securities sold in the past three months for the account in question.